Achilles Therapeutics

15 articles with Achilles Therapeutics

• Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting

  4/10/2021

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, presented a patient case study from the Company’s ongoing Phase I/IIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research Annual Meeting 2021.

• 

  Money on the Move: March 31 – April 6

  4/7/2021

  April springs up with showers of cash for these life sciences companies.

• Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

  4/6/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the closing of its previously announced initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares, at an initial public offering price of $18.00 per ADS

• Achilles Therapeutics Announces Pricing of Initial Public Offering

  3/30/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”)

• Achillion Shareholders Approve Agreement to be Acquired by Alexion

  12/19/2019

  Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.

• Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer

  10/21/2019

  Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019.

• Achilles Therapeutics raises £100 million in oversubscribed Series B financing

  9/3/2019

  Achilles Therapeutics announces it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.

• 

  BioSpace Movers and Shakers: Feb. 15

  2/15/2019

  Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.

• Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma

  2/13/2019

  Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of its Clinical Trial Application (CTA) to conduct a Phase I/II study using clonal neoantigen targeting T cells (cNeT) in patients with metastatic or recurrent melanoma.

• Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer

  2/12/2019

  Dr Dangl joins Achilles from Medigene AG where he spent three years as Senior Vice President for Research and Non-clinical Development.

• Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung Cancer

  1/21/2019

  Achilles Therapeutics (“Achilles””), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical Trial Application (CTA) to conduct a Phase I/II study with its lead product, a tumour-derived T cell therapy targeting clonal neoantigens, in development for the treatment of  advanced Non-Small Cell Lung Cancer (NSCLC), has been approved by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).

• Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer

  12/10/2018

  Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer immunotherapies, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors.

• Achilles To Support A Natural History Study Of C3 Glomerulopathy, A Rare Renal Disorder, Conducted By Experts At Imperial College London

  2/28/2017

• Achilles Starts 2017 With Move To Stevenage Bioscience Catalyst

  1/4/2017

• Syncona, Cancer Research Technology Launch Achilles With $17.5 Million

  10/6/2016